Cardiac AI: The Trillion-Dollar Question for Investors

By 2035, cardiovascular disease (CVD) is on track to cost the US over $1.1 trillion a year. For investors in healthcare AI, the tech itself is secondary to one question: can it actually lower these avoidable costs at a system-wide scale? The biggest challenge isn’t building the AI, it’s proving its financial value, and that’s especially true in preventative cardiology where the “savings” are events that didn’t happen.

The System-Level Economic Effects: From Acute Triage to Proactive Prevention

AI in cardiology is splitting into two distinct paths: tools that optimize acute care and platforms that aim to prevent acute events in the first place. You have to separate them to get a real picture of the system-level economics. Look at a company like Viz.ai, which is all about acute care coordination. Their AI platform speeds up how hospitals detect and triage time-sensitive conditions like stroke, getting care teams on the same page instantly. By cutting down the chaos and improving communication, Viz.ai gets patients treated faster. The data from their trials and real-world use shows this leads to quicker patient transfers and interventions, which directly reduces the long-term costs of disability and complications that follow a severe stroke Viz.ai stroke cost reduction data. This is why Tiger Global put $100 million into their Series D at a $1.2 billion valuation. The ROI in optimizing an acute emergency is clear and measurable. But the much bigger economic win comes from platforms that stop the cardiac event from ever happening. Instead of just managing the crisis, you’re getting ahead of the risk entirely. It’s the difference between being a great firefighter and actually fireproofing the building. AI-powered prevention is where the serious, long-term cost reductions are going to come from. A prime example from our own network is Hello Heart. They have peer-reviewed data showing their AI-driven blood pressure program saves an average of $1,709 per member annually and cuts inpatient admissions for heart-related events by 47% Hello Heart peer-reviewed ROI study. The value proposition here is totally different from acute care. It’s about preventing the stroke from happening at all, or at least pushing it off and making it less severe if it does occur.

A Prescriptive Framework for Evaluating Preventative AI ROI

Investors need a framework for evaluating these prevention-focused AI platforms that goes past the headline valuation. The focus must be on the system-level economic effects, which are built on a foundation of individual patient outcomes. I use the following checklist:

• Clinical Validation and Real-World Evidence (RWE): Demand strong, peer-reviewed clinical studies. For prevention, that means hard data showing a statistically significant drop in risk factors (like blood pressure, cholesterol, or A1c) or, even better, a reduction in actual heart attacks and hospitalizations. Your confidence as an investor should be based on their statistical analysis of real-world data (RWD), proving the model works across large, messy populations and not just in a small, clean pilot study.
• Mechanism of Cost Reduction: You need to pinpoint exactly where the savings come from. Is it… * Reduced Acute Events: As demonstrated by Hello Heart, preventing ER visits, hospital stays, and expensive interventions is the most direct path to savings. This is the top prize.
• Optimized Resource Utilization: The AI should be able to separate the truly high-risk patients who need expensive care from the “worried well” who can be managed with cheaper measures, saving specialist time.
• Improved Medication Adherence/Lifestyle Modification: The platform has to actually get patients to take their meds and change their habits. Personalized AI nudges are key, because adherence is the foundation of preventing CVD’s progression.
• Early Detection and Intervention: Look for platforms that find risk sooner and more accurately. The work being done by companies like Tempus AI, integrating genomic and cardiac data, allows doctors to step in when treatment is simpler and cheaper. GV’s investment in Tempus AI signals the market’s belief in this kind of AI-driven patient stratification and personalized care.
• Scalability and Implementation Ease: The tech has to plug into existing healthcare workflows without causing a revolt among the staff, and it must be able to scale to cover huge patient populations. A solution that requires an army of specialists to run is already a failure from a cost perspective. You also have to scrutinize the regulatory and reimbursement path. Do they have 510(k) clearance or, for new functions, a De Novo classification? Is there any realistic shot at getting CPT codes so people can actually get paid to use it?
• Data Moat and Algorithmic Resilience: A company needs a proprietary data set that gives it a real competitive edge and feeds back into making the AI smarter. But just as important, you have to ask how they handle algorithmic drift. What happens when the real-world patient data starts to look different from the training data? A model that isn’t actively monitored will lose its accuracy. Companies that can point to strong GMLP (Good Machine Learning Practice) and a PCCP (Predetermined Change Control Plan) are thinking about the long-term stability of their product.
• Avoidance of “Zombie Company” Traps: A slick pitch and impressive tech are not a business model. Investors need to dig into the go-to-market strategy and actual traction. The spectacular collapse of Olive AI, which burned through over $900 million before shutting down, is a brutal lesson that a mountain of cash can’t save a company without a viable commercialization strategy that delivers clear ROI. Tiger Global’s experience there shows you have to vet the business plan as hard as you vet the code.
  

  Methodology Note: The Primacy of Real-World Data Analysis

Any ROI claim for preventative AI is only as good as its statistical analysis of Real-World Data (RWD). While randomized controlled trials (RCTs) are the benchmark for clinical effectiveness, to see the true economic impact across a messy health system, you need RWD pulled from electronic health records, claims data, and patient-generated health data. It’s the only way to see what’s really happening. This analysis includes:

• Comparative Effectiveness Research: This means comparing the outcomes and total costs for a group using the AI against a control group getting standard care, making sure to statistically adjust for any confounding variables.
• Claims Data Analysis: This is where the rubber meets the road, you’re looking at raw insurance claims data to count the actual reduction in medical spending, hospital days, ER visits, and prescription costs.
• Propensity Score Matching: This is a key statistical method used with RWD. It creates an apples-to-apples comparison by matching individuals in the AI group with similar individuals in the control group, helping to isolate the true effect of the intervention. A company’s willingness to be transparent about its analytical methods is a huge green flag. If they can show you statistically sound RWE instead of just marketing projections, you have a much better shot at seeing a real return. Of course, all of this has to be built on a foundation of strict data security and privacy, adhering to standards like HIPAA, HITRUST, and SOC 2 HIPAA compliance guidelines for health data. The AI platforms in cardiology that will actually win are the ones that can prove, with hard data, that they lower the total system cost of CVD. That proof comes from validated clinical results and real-world savings, shifting the entire financial model from fixing acute problems to preventing them from ever starting. For an investor, that’s the only story that matters.